Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
BOSTON, May 30, 2017 -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Jefferies 2017 Healthcare Conference in New York City on Tuesday, June 6, 2017 at 1:30 p.m. Eastern Time.
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT: Lora Pike Senior Director, Investor Relations & Corporate Communications T: 617-466-3511 [email protected]
